208 related articles for article (PubMed ID: 22146597)
21. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer.
Froehner M; Hakenberg OW; Koch R; Schmidt U; Meye A; Wirth MP
Urol Int; 2006; 76(1):27-30. PubMed ID: 16401917
[TBL] [Abstract][Full Text] [Related]
22. Prostate-specific antigen: insufficient discrimination between benign prostatic hyperplasia and organ-confined prostate cancer.
Wolff JM; Boeckmann W; Borchers H; Handt S; Reineke T; Jakse G
Urol Int; 1996; 57(3):170-4. PubMed ID: 8912446
[TBL] [Abstract][Full Text] [Related]
23. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
[TBL] [Abstract][Full Text] [Related]
24. Plasma Sarcosine Measured by Gas Chromatography-Mass Spectrometry Distinguishes Prostatic Intraepithelial Neoplasia and Prostate Cancer from Benign Prostate Hyperplasia.
Markin PA; Brito A; Moskaleva N; Fodor M; Lartsova EV; Shpot YV; Lerner YV; Mikhajlov VY; Potoldykova NV; Enikeev DV; Lyundup AV; Appolonova SA
Lab Med; 2020 Nov; 51(6):566-573. PubMed ID: 32161964
[TBL] [Abstract][Full Text] [Related]
25. Inter-relation between measurement of serum prostatic specific antigen and transrectal ultrasound in the diagnosis of benign prostatic hyperplasia and prostatic cancer.
Clements R; Etherington RJ; Griffiths GJ; Peeling WB; Hughes H; Penney MD
Br J Urol; 1992 Aug; 70(2):183-7. PubMed ID: 1382795
[TBL] [Abstract][Full Text] [Related]
26. Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy.
Marrink J; Oosterom R; Bonfrer HM; Schröder FH; Mensink HJ
Eur J Cancer; 1993; 29A(4):570-1. PubMed ID: 7679580
[TBL] [Abstract][Full Text] [Related]
27. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
28. Improved detection of prostate cancer using a magneto-nanosensor assay for serum circulating autoantibodies.
Xu L; Lee JR; Hao S; Ling XB; Brooks JD; Wang SX; Gambhir SS
PLoS One; 2019; 14(8):e0221051. PubMed ID: 31404106
[TBL] [Abstract][Full Text] [Related]
29. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
Roehrborn CG; Gregory A; McConnell JD; Sagalowsky AI; Wians FH
Urology; 1996 Dec; 48(6A Suppl):23-32. PubMed ID: 8973696
[TBL] [Abstract][Full Text] [Related]
30. What is the 'normal range' for prostate-specific antigen? Use of a receiver operating characteristic curve to evaluate a serum marker.
Gillatt D; Reynard JM
Br J Urol; 1995 Mar; 75(3):341-6. PubMed ID: 7537603
[TBL] [Abstract][Full Text] [Related]
31. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
Jung K; Elgeti U; Lein M; Brux B; Sinha P; Rudolph B; Hauptmann S; Schnorr D; Loening SA
Clin Chem; 2000 Jan; 46(1):55-62. PubMed ID: 10620572
[TBL] [Abstract][Full Text] [Related]
32. Prostate-specific antigen (PSA) and cancer-associated serum antigen (CASA) in distinguishing benign and malignant prostate disease.
Devine PL; Walsh MD; McGuckin MA; Quin RJ; Hohn BG; Clague A; Samaratunga H
Int J Biol Markers; 1995; 10(4):221-5. PubMed ID: 8750649
[TBL] [Abstract][Full Text] [Related]
33. Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer.
Romppanen J; Haapalainen T; Punnonen K; Penttilä I
Anticancer Res; 2002; 22(1A):415-20. PubMed ID: 12017325
[TBL] [Abstract][Full Text] [Related]
34. Cytokeratin 8/18 levels in patients with prostate cancer and benign prostatic hyperplasia.
Wolff JM; Borchers H; Brehmer B; Brauers A; Jakse G
Urol Int; 1998; 60(3):152-5. PubMed ID: 9644784
[TBL] [Abstract][Full Text] [Related]
35. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
36. Complexed and total PSA in patients with benign prostatic hyperplasia and prostate cancer.
Tamimi W; Dafterdar R; Mansi M; Alsaad K; Alarifi SA
Br J Biomed Sci; 2010; 67(4):184-8. PubMed ID: 21294445
[TBL] [Abstract][Full Text] [Related]
37. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
[TBL] [Abstract][Full Text] [Related]
38. Usefulness of prostate-specific antigen density as a diagnostic test of prostate cancer.
Filella X; Alcover J; Molina R; Carrere W; Carretero P; Ballesta AM
Tumour Biol; 1996; 17(1):20-6. PubMed ID: 7501969
[TBL] [Abstract][Full Text] [Related]
39. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
[TBL] [Abstract][Full Text] [Related]
40. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]